A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.

Peng, Chien-Wei; Jeng, Wen-Juei; Yang, Hwai-I; Liu, Yen-Chun; Chien, Rong-Nan; Liaw, Yun-Fan

Peng, Chien-Wei; Jeng, Wen-Juei; Yang, Hwai-I; Liu, Yen-Chun; Chien, Rong-Nan; Liaw, Yun-Fan.

Afiliação

Peng CW; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.
Jeng WJ; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yang HI; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.
Liu YC; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chien RN; Genomic Research Center, Academia Sinica, Taipei, Taiwan.
Liaw YF; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.

J Gastroenterol Hepatol ; 37(11): 2164-2172, 2022 Nov.

Article em En | MEDLINE | ID: mdl-35869752

Assuntos

Hepatite B Crônica; Humanos; Tenofovir/uso terapêutico; Hepatite B Crônica/tratamento farmacológico; Antígenos E da Hepatite B; Vírus da Hepatite B/genética; Antivirais; DNA Viral; Resultado do Tratamento; Exacerbação dos Sintomas; Recidiva; Suspensão de Tratamento

Palavras-chave

adefovir; cessation; clinical relapse; hepatic decompensation; hepatitis B flare; lamivudine; nucleos(t)ide analogue; sustained response; telbivudine; tenofovir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google